AnaptysBio, Inc. (ANAB) News

AnaptysBio, Inc. (ANAB): $28.55

0.02 (+0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

Filter ANAB News Items

ANAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ANAB News Highlights

  • For ANAB, its 30 day story count is now at 2.
  • Over the past 2 days, the trend for ANAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • GPP and RARE are the most mentioned tickers in articles about ANAB.

Latest ANAB News From Around the Web

Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules. The 16-week data were presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress. Data from 8 patients showed that 6/8 patients treated with imsidolimab monotherapy achieved the primary endpoint of response on the clinical global impre

Yahoo | October 4, 2021

AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduction at week 16Phase 3 GEMINI-1 clinical trial has been initiated subsequent to FDA end-of-Phase 2 meeting and FDA orphan drug designation for the treatment of GPPIn addition to GPP, imsidolimab clinical development to foc

Yahoo | October 2, 2021

Anaptysbio Inc (ANAB): Price Now Near $26.51; Daily Chart Shows An Uptrend on 20 Day Basis

The moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment -- meaning the shorter durations are above the longer duration averages, implying a sound upward trend. The post Anaptysbio Inc (ANAB): Price Now Near $26.51; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .

ETF Daily News | September 17, 2021

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on Monday

Yahoo | September 9, 2021

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV) Alkermes plc (NASDAQ: ALKS) Century Therapeutics Inc (NASDAQ: IPSC) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) Edward Lifesciences Corp (NYSE: EW) Eli Lilly and Company (NYSE: LLY) (announced reorganization of business units) Innoviva Inc (NASDAQ: INVA) Intuitive Surgical, Inc. (NASDAQ: ISRG) Johnson

Yahoo | August 18, 2021

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication

The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment and have no satisfactory alternative treatment options. Jemperli was approved for dMMR endometrial cancer in the U.S. and Europe in April. Related content: Benzinga's Full FDA Calendar. Jemperli was generated by AnaptysBio Inc (

Yahoo | August 18, 2021

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSKs JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

Intrado Digital Media | August 17, 2021

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April 2021$20MM Milestone Payment Earned by AnaptysBio Upon Second JEMPERLI FDA Approval in Addition to $40MM Already Earned Upon Prior Regulatory Milestones During 2021Additional $15MM and $165MM Milestones Due Upon Achievement of JEMPERLI Regulatory and Commercial Milestones, RespectivelyAnaptysBio Due to

Yahoo | August 17, 2021

Global Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBio

Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com''s offering. This ''Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030'' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Netherton Syndrome Epidemiology The Netherton Syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studi...

Intrado Digital Media | August 12, 2021

Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies

Los Angeles, USA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies Approximately 10+ key companies are developing therapies for Peanut Allergy treatment. DBV Technologies has its drug candidates in the most advanced stage. The use of new biological compounds is considered to have the potential to treat the disease, which is expected to improve the treatment method in Peanut Allergy patients. DelveInsight''s " Peanut Allergy Pipeline Insight " report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Peanut Allergy pipeline landscapes. It comprises Peanut Allergy pipeline drug profiles, including clinical and non-clinical stage produc...

Benzinga | August 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.8106 seconds.